Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "Novartis"

118 News Found

Novartis signs world’s first agreement with NHS, UK
News | September 03, 2021

Novartis signs world’s first agreement with NHS, UK

The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England


Novartis secures new approval in China for Cosentyx in pediatric psoriasis
Drug Approval | August 18, 2021

Novartis secures new approval in China for Cosentyx in pediatric psoriasis

Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch


Novartis announces positive results from Phase 3 trials of Beovu for diabetes
Drug Approval | August 18, 2021

Novartis announces positive results from Phase 3 trials of Beovu for diabetes

Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one


Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development
People | July 31, 2025

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development

He most recently served as Chief Medical Officer of AstraZeneca and Alexion


Alembic Pharmaceuticals announces USFDA final approval for Carbamazepine ER Tablets USP
Drug Approval | July 27, 2025

Alembic Pharmaceuticals announces USFDA final approval for Carbamazepine ER Tablets USP

Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug


Alembic announces USFDA Final Approval for Carbamazepine Tablets USP, 200 mg
Drug Approval | April 17, 2025

Alembic announces USFDA Final Approval for Carbamazepine Tablets USP, 200 mg

Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA


NATCO announces approval of its ANDA for Everolimus tablets for Oral Suspension
Drug Approval | January 31, 2025

NATCO announces approval of its ANDA for Everolimus tablets for Oral Suspension

Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma


Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg
News | December 06, 2024

Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg

The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA


Suven Pharma appoints Declan Ryan as CCO
People | October 15, 2024

Suven Pharma appoints Declan Ryan as CCO

Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors


Alembic appoints Sudhakar Pandiyan as Head - Technical Operations
People | September 17, 2024

Alembic appoints Sudhakar Pandiyan as Head - Technical Operations

He has been associated with Caplin Steriles Ltd., Mylan Laboratories Ltd., Caplin Point Laboratories Ltd., Strides Arcolab Ltd. and Novartis Vaccines and Diagnostics